A5039623172- RNA and protein synthesis mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Toxin Mechanisms and Immunotoxins
- Enzyme Structure and Function
- Immune Cell Function and Interaction
- Peptidase Inhibition and Analysis
- Kruppel-like factors research
- Protein purification and stability
- Cancer therapeutics and mechanisms
- Computational Drug Discovery Methods
- Mass Spectrometry Techniques and Applications
- Receptor Mechanisms and Signaling
- Radiopharmaceutical Chemistry and Applications
- Wnt/β-catenin signaling in development and cancer
- Protein Degradation and Inhibitors
- Biosimilars and Bioanalytical Methods
- Cancer-related gene regulation
- Multiple Myeloma Research and Treatments
- T-cell and B-cell Immunology
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- IL-33, ST2, and ILC Pathways
- Orthopaedic implants and arthroplasty
- Tuberculosis Research and Epidemiology
Immunocore (United Kingdom)
2024
Institute of Structural and Molecular Biology
2018
University of Leicester
2013-2018
RNA polymerase-binding protein A (RbpA), encoded by Rv2050, is specific to the actinomycetes, where it highly conserved. In pathogen Mycobacterium tuberculosis, RbpA essential for growth and survival. binds β subunit of polymerase activates transcription unknown mechanisms, may also influence response M. tuberculosis current frontline anti-tuberculosis drug rifampicin. Here we report solution structure identify principle sigma factor σ(A) stress-induced σ(B) as interaction partners. The has...
Tralokinumab, a fully human mAb specifically targeting the IL-13 cytokine, has demonstrated clinical efficacy and safety in patients with moderate-to-severe atopic dermatitis. Tralokinumab binds high affinity, which prevents interaction of IL-13Rα1 subsequent signaling. Similarly, tralokinumab-bound cannot bind to IL-13Rα2, proposed decoy receptor that is reported extraordinarily affinity. It however not been elucidated what extent tralokinumab interferes endogenous regulation through...
Specific, high affinity protein-protein interactions lie at the heart of many essential biological processes, including recognition an apparently limitless range foreign proteins by natural antibodies, which has been exploited to develop therapeutic antibodies. To mediate protein complexes need form on appropriate, relatively rapid timescales, presents a challenge for productive engagement with large and complex contact surfaces (∼600-1800 Å(2)). We have obtained comprehensive backbone NMR...
Abstract Over recent years, Induced proximity therapeutics (IPT) and targeted protein degradation (TPD) approaches have become increasingly popular. Whilst significant initial efforts focused upon heterobifunctional degraders, molecular glue degraders (MGDs) represent the next generation proximity-based drugs, but their rational discovery remains challenging. Here, we describe unbiased broadly applicable for hit ID through development of a suite orthogonal highly complementary screening...
PRAME (
Abstract Molecular glue degraders are compact, low molecular weight molecules that can efficiently induce specific and potent degradation of a target protein. This class function by inducing interactions between interest ubiquitin-ligase, either stabilization weak pre-existing interactions, or generation entirely novel interactions. These offer significant opportunity beyond heterobifunctional such as PROTACs, not least in terms improved properties. However, the IMID glues, typified...